Highlights
KLSE: YSPSAH (7178)       Y.S.P. SOUTHEAST ASIA HOLDING BHD MAIN : Health Care
Last Price Today's Change   Day's Range   Trading Volume
2.35   +0.02 (0.86%)  2.35 - 2.40  33,500
Analyze this stock with MQ Trader system

Financials


Market Cap: 328 Million

Market Cap 328 Million
NOSH 140 Million

Latest Audited Result:  31-Dec-2017

Latest Audited Result: 31-Dec-2017
Announcement Date 26-Apr-2018
Next Audited Result: 31-Dec-2018
Est. Ann. Date: 26-Apr-2019
Est. Ann. Due Date: 29-Jun-2019

Latest Quarter:  30-Sep-2019 [#3]

Latest Quarter: 30-Sep-2019 [#3]
Announcement Date 19-Nov-2019
Next Quarter: 31-Dec-2019
Est. Ann. Date: 26-Feb-2020
Est. Ann. Due Date: 29-Feb-2020
QoQ | YoY   26.38%  |    25.06%

Annual (Unaudited) ( EPS: 21.74, P/E: 10.81 )

Revenue | NP to SH 288,759  |  30,350
RPS | P/RPS 206.87 Cent  |  1.14
EPS | P/E | EY 21.74 Cent  |  10.81  |  9.25%
DPS | DY | Payout % 6.93 Cent  |  2.95%  |  31.89%
NAPS | P/NAPS 2.26  |  1.04
YoY   48.91%
NP Margin | ROE 10.44%  |  9.63%
F.Y. | Ann. Date 31-Dec-2018  |  26-Feb-2019

T4Q Result ( EPS: 18.68, P/E: 12.58 )

Revenue | NP to SH 294,544  |  26,068
RPS | P/RPS 211.02 Cent  |  1.11
EPS | P/E | EY 18.68 Cent  |  12.58  |  7.95%
DPS | DY | Payout % 8.46 Cent  |  3.60%  |  45.31%
NAPS | P/NAPS 2.34  |  1.00
QoQ | YoY   6.58%  |    -8.94%
NP Margin | ROE 8.67%  |  7.98%
F.Y. | Ann. Date 30-Sep-2019  |  19-Nov-2019

Annualized Result ( EPS: 18.36, P/E: 12.80 )

Revenue | NP to SH 291,337  |  25,633
RPS | P/RPS 208.72 Cent  |  1.13
EPS | P/E | EY 18.36 Cent  |  12.80  |  7.81%
DPS | DY | Payout % -
NAPS | P/NAPS -
QoQ | YoY   14.53%  |    -18.22%
NP Margin | ROE 8.63%  |  7.85%
F.Y. | Ann. Date 30-Sep-2019  |  19-Nov-2019



Business Performance

Business Performance (By Quarter)

Trailing 4 Quarters Trailing 8 Quarters
Available Quarters 4 Quarters 8 Quarters
Continuous Quarters Of Revenue Growth 1 / 4 25.00% 1 / 8 12.50%
Total Positive Profit Years 4 / 4 100.00% 8 / 8 100.00%
Continuous Quarters Of Positive Profit 4 / 4 100.00% 8 / 8 100.00%
Continuous Quarters Of Profit Growth 2 / 4 50.00% 2 / 8 25.00%
Continuous Quarters Of Adjusted EPS Growth 2 / 4 50.00% 2 / 8 25.00%
Total Dividend Years 1 / 4 25.00% 2 / 8 25.00%
Continuous Quarters Of Dividend 0 / 4 0.00% 0 / 8 0.00%
Continuous Quarters Of Dividend Growth 0 / 4 0.00% 0 / 8 0.00%
Continuous Quarters Of Adjusted Dps Growth 0 / 4 0.00% 0 / 8 0.00%
Average ROE 2.04% 2.22%
Average Net Profit Margin 8.68% 9.44%

Business Performance (By Year)

Last 5 Financial Years Last 10 Financial Years
Available Years 5 Years 10 Years
Continuous Years Of Revenue Growth 5 / 5 100.00% 10 / 10 100.00%
Total Positive Profit Years 5 / 5 100.00% 10 / 10 100.00%
Continuous Years Of Positive Profit 5 / 5 100.00% 10 / 10 100.00%
Continuous Years Of Profit Growth 1 / 5 20.00% 1 / 10 10.00%
Continuous Years Of Adjusted EPS Growth 1 / 5 20.00% 1 / 10 10.00%
Total Dividend Years 5 / 5 100.00% 6 / 10 60.00%
Continuous Years Of Dividend 5 / 5 100.00% 5 / 10 50.00%
Continuous Years Of Dividend Growth 0 / 5 0.00% 0 / 10 0.00%
Continuous Years Of Adjusted Dps Growth 0 / 5 0.00% 0 / 10 0.00%
Average ROE 9.00% 8.20%
Average Net Profit Margin 10.30% 9.61%

Key Result

Key Result

T4Q Annualized Annual (Unaudited) Last 10 FY Average Last 5 FY Average
Revenue 294,544 291,337 288,759 200,999 242,506
NP to SH 26,068 25,633 30,350 19,320 24,757
Dividend 11,811 15,819 9,679 5,522 9,883
Adjusted EPS 18.68 18.36 21.74 13.84 17.74
Adjusted DPS 8.46 11.33 6.93 3.96 7.08

NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share

All figures in '000 unless specified.

EPS & DPS's figures in Cent.


Growth

Growth (By Quarter)

LQ QoQ LQ YoY CQ YoY LQ vs Average of T4Q LQ vs Average of T8Q
Revenue 6.57% 1.22% 2.72% 0.72% 3.14%
NP to Owner 26.38% 25.06% -18.22% 23.28% 17.51%
Dividend 0.00% 0.00% 22.79% 0.00% 0.00%
Adj. EPS 26.38% 25.06% -18.22% 23.28% 17.51%
Adj. DPS 0.00% 0.00% 22.79% 0.00% 0.00%

LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year

Growth (By Year)

T4Q vs LFY T4Q vs AL5FY T4Q vs AL10FY AQR vs LFY AQR vs AL5FY AQR vs AL10FY LFY YoY LFY vs AL5FY LFY vs AL10FY
Revenue 2.00% 21.46% 46.54% 0.89% 20.14% 44.94% 10.40% 19.07% 43.66%
NP to Owner -14.11% 5.29% 34.93% -15.54% 3.54% 32.68% 48.91% 22.59% 57.09%
Dividend 22.03% 19.51% 113.87% - % - % - % -16.72% -2.07% 75.25%
Adj. EPS -14.11% 5.29% 34.93% -15.54% 3.54% 32.68% 48.91% 22.59% 57.09%
Adj. DPS 22.03% 19.51% 113.87% - % - % - % -16.72% -2.07% 75.25%

T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year

Trade this stock for as low as 0.05% brokerage. Find out more.
  4 people like this.
 
stockraider The look at how the logistic structured ? It still point to monopoly loh.....!!

Why must u restrict the monopoly of govt drug logistic to only 3 provider leh ??

Why not allow up to 20 to 30 suppliers leh ??
11/09/2019 11:08 AM
kalofarmako “The big problem is price control, not Pharmaniaga,” says MyCC

Social activist Lim Mah Hui, one of the conductors of the MyCC study, said Pharmaniaga did not have a monopoly over supply but a virtual monopoly over logistics.

Check out: https://klse.i3investor.com/blogs/MYpharmaceuticalnews/224759.jsp
13/09/2019 9:53 AM
stockraider Post removed. Why?
13/09/2019 10:17 AM
stockraider The govt give very stupid excuse loh....if u do not let suppliers sell direct and also distribute competitively to the govt, how the hell u can ensure the drug price...is bought competitively leh ??
13/09/2019 10:22 AM
ValueMe Collected few lots today :)Not many YSP shares on sale.
27/09/2019 1:26 PM
RainT @valueme

YSPSAH liquidity is very low

very hard to trade

the buy and sell price also gap very big

its good company , just the numbre of shares is very low

why the company dont do bonus or split so the number of shares can be more and improve trading liquidity
27/09/2019 7:37 PM
RainT Lee Fang Shin buy more shares

good ...
27/09/2019 7:43 PM
ValueMe @RainT

If liquidity is increased,it will become a speculative stock..I reckon its better if the company doesn't issue shares...Bonus or split wont happen now as PE ratio is low :)
27/09/2019 9:02 PM
Up_down No catalyst yet but it's still a good bargain at this price level.
30/09/2019 2:17 PM
RainT grab more at 2.28 today

hope 2.28 is strong support

dont break it, if not really no eyes see lo
03/10/2019 3:40 PM
RainT @valueMe

yes, you have your points

but if no split or bonus, YSPSAH shares is too low, very low volume

if you want sell or buy, the gap price very big

and due to small quantity of shares, just a small buy or sell will fluctuate the share price a lot

Have good and bad sides also, but i hope YSPSAH shares can be more liquid
03/10/2019 3:43 PM
RainT lee fang shin buy at 25/09/2019

price range is 2.35 - 2.30

any price below this is good buy

especially if can get 2.28 is good
03/10/2019 3:44 PM
RainT @up_down

if you read more , catalyst for YSPSAH is

expan to Indonesia at end 2019

new R&D to open

capacity to increase 30%

invest new equipment in 2nd half 2019
03/10/2019 3:46 PM
Up_down RainT. No exciting now but it's OK since the prices have been staying ut quite low in comparing with peers. Expecting YSPSAH to deliver better QR in next few quarters after taking into account contributions from expansion.
03/10/2019 3:59 PM
ValueMe @ Rain T.
2.28 is a good price to collect. Good luck with your purchase.

Those who can't keep long term have to let go.

African swine fever worsening and is affecting YSP veterinary drugs sales for hogs. Its a temporary reduction for sales in this segment. Drug sales for humans and other poultry animals should be intact.
03/10/2019 10:38 PM
kalofarmako The public need to understand that Pharmaniaga's role as a concessionaire and not immediately liken it to a monopoly. Shared some thoughts in this article (https://klse.i3investor.com/blogs/MYpharmaceuticalnews/228733.jsp). Though it could use a bit more context but hope this can get the conversation going.

Source: http://read.focusmalaysia.my/ePaper/xml_epaper/Focus/05_10_2019/pla_1_Standard/xml_arts/art_52429.htm
07/10/2019 4:24 PM
RainT Pharmaniaga is the source medicine from supplier and then supply to government hospital & clinic so u can see their margin is very thin only

YSPSAH is they produce the medicine &do R&D and manufacture the medicine , so the gross margin and net margin of YSPSAH is much higher than PHARMANIAGA

both in same industry but biz style is totally different , cannot compare
09/10/2019 4:49 PM
mindshare bila mahu naik?
24/10/2019 4:33 PM
ValueMe YSP, Doupharma and Kotra medications are more effective compared to Pharmaniaga medications. Most General Practitioners in the private sector know that. Government had to decide at the end if patient's satisfaction is more important compared to cronism.
31/10/2019 3:24 PM
bunuhsateman susah la macam nie... tak gerak langsung
06/11/2019 9:53 AM
kalofarmako Pharmaniaga's services would be extended until the Cabinet decides on the mechanism to manage the open tender.

source link: https://klse.i3investor.com/blogs/MYpharmaceuticalnews/234024.jsp
https://klse.i3investor.com/blogs/MYpharmaceuticalnews/234024.jsp
06/11/2019 2:58 PM
RainT YSPSAH volume so low

cannot move
08/11/2019 12:49 AM
kalofarmako Pharmaniaga Bhd witnessed a 300% spike in orders, largely from hospitals and government clinics after the government announced the firm’s drugs and medical supply concession would end on Nov 30.

Check this out!!! https://klse.i3investor.com/blogs/MYpharmaceuticalnews/234455.jsp
08/11/2019 10:53 AM
kalofarmako POSITIVE REACTION ON PHARMANIAGA EXTENSION

Sources Link:https://klse.i3investor.com/blogs/MYpharmaceuticalnews/234829.jsp
11/11/2019 4:44 PM
kalofarmako Check this out!!!

Sources Link:https://klse.i3investor.com/blogs/MYpharmaceuticalnews/234991.jsp
12/11/2019 11:13 AM
mindshare ada movement....ada news?
12/11/2019 4:40 PM
kalofarmako PHARMANIAGA STOCK RECORD YEAR’S STRONGEST JUMP

Check this out!!!

https://klse.i3investor.com/blogs/MYpharmaceuticalnews/235081.jsp
12/11/2019 5:21 PM
Fabien "The Efficient Capital Allocater" heath care is resilient. it's less impacted by trade war or economic cylicality and more influenced by secular growth
13/11/2019 11:04 AM
shawn88 should be up .. due to pharma
13/11/2019 11:24 AM
kalofarmako Pharmaniaga Bhd confirms today that it has secured a five-year extension for the provision of logistics and distribution services to the Ministry of Health, to end on Dec 31, 2024.

Check this out:
https://klse.i3investor.com/blogs/MYpharmaceuticalnews/237671.jsp
19/11/2019 11:41 AM
RainT wah

good result out also not people come huhahuha

this counter really thin trading volume & not popular

good fundamental company but nobody is interested
20/11/2019 9:39 AM
ValueMe YMCA..its fun to stay at YMCA..HUATAH!
20/11/2019 9:40 AM
RainT the quarter report review performance seem like dont write anything good information for minority shareholders

the management should disclose more
20/11/2019 9:46 AM
kalofarmako https://klse.i3investor.com/blogs/MYpharmaceuticalnews/238123.jsp

Govt extends Pharmaniaga services for medicines, medical supplies
20/11/2019 12:01 PM
ValueMe Pharmaniaga pi tidukla...go see your quarterly results. Next time do promote more of Pharmaniaga in Ysp forums.Kihkihkih.
20/11/2019 2:26 PM
Fabien "The Efficient Capital Allocater" It's good news for YSP too.

From CIMB report:
We expect YSP to record stronger 4Q19 results, in tandem with higher drug demand
from government medical facilities. This is premised on: i) 4Q being a seasonally stronger
period, and ii) government facilities increasing drug orders with its suppliers due to earlier
concerns of a disruption to medical supply on expectations that the government would
not renew Pharmaniaga’s concession agreement (CA) to provide logistics and distribution
services for drugs under approved product purchase list (APPL). It has since been
announced that Pharmaniaga has obtained two extensions for services under the CA
20/11/2019 3:10 PM
Fabien "The Efficient Capital Allocater" Next year EPS should normalise, back to growth trajectory.

CIMB TP 3.65:
We maintain our Add call with a higher TP of RM3.65 (12.3x CY21F P/E) as we roll over
our valuation year to end-2020F. We continue to like YSP for: i) its attractive valuation of
9.6x CY21 P/E (22% discount to its 5-year historical mean of 12.3x), ii) its net cash
position of RM47.7m (as at end-3Q19), and iii) the inelastic demand for drugs. Potential
re-rating catalysts are stronger-than-expected sales locally and regionally. Downside
risks to our call: decline in sales volume and continued losses in its Vietnam operations.
20/11/2019 3:12 PM
RainT 4Q is seasonally strong qtr??

if u see past sales and profit of Q4 it is not the stronger one lo
20/11/2019 11:36 PM
RainT also the PHARMA story not affect to YSPSAH lo

both is different biz even both also do medicine

so u can see the margin of YSPSAH is much higher than PHARMA lo
20/11/2019 11:37 PM
shawn88 YSP Southeast Asia Holding Bhd
(Nov 20, RM2.50)
Maintain buy with an unchanged target price (TP) of RM3: Despite recording a weaker third quarter of financial year 2019 (3QFY19) core net profit (CNP) (-9% year-on-year [y-o-y]), YSP Southeast Asia Holding Bhd’s y-o-y earnings contraction has narrowed, while earnings were actually stronger on a quarter-on-quarter (q-o-q) basis. This was despite 3Q typically being a seasonally weak quarter. This reaffirms our view that YSP is on the road to recovery as its new equipment is running at more efficient rates. We maintain our earnings forecasts and reiterate our “buy” call on YSP with an unchanged TP of RM3.


YSP reported a flattish revenue of RM74 million (+1% y-o-y) for 3QFY19 as the growth in domestic sales (+3% y-o-y) was offset by soft overseas sales (-4% y-o-y). While its CNP continued to decline by 9% y-o-y, we think the results are showing signs of recovery as the y-o-y earnings contraction narrowed to only -9% for 3QFY19 from an average -36% for the past three consecutive quarters, despite the unfavourable foreign exchange rate in 3Q19 (3Q18: RM4.09/US$ versus 3Q19: RM4.16/US$). We believe this was mainly due to an improvement in margins as its new equipment is running at more efficient rates. The results were in line with expectations.

Sequentially, YSP’s CNP recorded a significant 19% improvement for 3QFY19. Based on the historical three-year average data, 3Q is typically a seasonally weak quarter, making up only 18%-19% of its profit before tax and CNP.

With both the narrowed y-o-y decline in CNP and the q-o-q improvement in 3QFY19, we think that YSP is on the road to recovery following the initial start-up expenses for its new equipment which it incurred in the past few quarters. We continue to expect margins to improve gradually in the coming quarters.

We maintain our earnings forecasts, “buy” rating and TP of RM3, based on an unchanged target price-earnings ratio of 14 times. Downside risks include weakening of the ringgit against the US dollar, product recalls and regulatory risks. — Affin Hwang Capital, Nov 20
21/11/2019 1:24 PM
kalofarmako Now that govt is removing concession, its a smart move for Pharmaniaga to focus on diversifying
22/11/2019 11:10 AM
kalofarmako https://klse.i3investor.com/blogs/MYpharmaceuticalnews/240245.jsp

PHARMANIAGA MAY STILL HAVE THE UPPER HAND
26/11/2019 2:43 PM
RainT really kesian

after good quarter result out and 1 days show

and continue down until now
02/12/2019 4:50 PM
kalofarmako Pharmaniaga is contributing to non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) to support the registration of a new treatment for those with hepatitis C in Malaysia.

https://klse.i3investor.com/blogs/MYpharmaceuticalnews/242914.jsp
03/12/2019 9:15 AM
mindshare apasal tak habis habis Pharmaniaga kat sini...wrong thread la bro..
10/12/2019 4:17 PM
mindshare pi jauh jauh main la
10/12/2019 4:17 PM
mindshare Share YSP tak laku
11/12/2019 8:40 PM
kalofarmako Good news from Pharmaniaga!!!

https://klse.i3investor.com/blogs/MYpharmaceuticalnews/247439.jsp
13/12/2019 2:53 PM
shawn88 Next qr should be good.. get orders from big brand
24/12/2019 2:33 PM
kalofarmako Lets take a look!

https://klse.i3investor.com/blogs/MYpharmaceuticalnews/2019-12-31-story-h1481975295-PHARMANIAGA_READY_TO_FACE_2020.jsp
31/12/2019 9:33 AM